Clinical Trial Update: Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial updating immunogenicity and safety of NBP608 compared to Varivax in healthy children aged 12 months to 12 years with varicella.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Varicella

Drugs mentioned

• NBP608
• Varivax (varicella vaccine (live attenuated))

Snippet

Sponsor: SK Bioscience Co., Ltd. | Conditions: Varicella | Phase 3 | Status: COMPLETED